肿瘤患者预后的判断:AG825对3种非小细胞肺癌细胞系的生长抑制作用

Prognostic diagnosis of tumor patients: growth inhibition effect of AG825 on three kinds of non small cell lung cancer cell lines

目的观察HER2受体酪氨酸激酶抑制剂AG825对非小细胞肺癌(nonsmallcelllungcancer,NSCLC)细胞系的生长抑制作用。方法采用体外药物敏感性实验(MTT比色法),观察不同浓度的AG825分别作用24,96h对3种人类NSCLC细胞系A549,H322,H1299的生长抑制作用。结果AG825用药24h对A549,H322,H1299的抑制率分别为24.03%,25.87%,17.35%,用药(100μm)96h分别为78.31%,65.28%,63.98%。AG825对A549,H322,H1299的半数抑制浓度分别为7.31,16.29,1.769μm。结论AG825对3种NSCLC细胞系具有生长抑制作用,这种作用呈时间依赖性和浓度依赖性。

AIM: To observe the growth inhibitory effect of tyrosine kinase inhibitor AG825 of human epidermal growth factor receptor(HER2) on non small cell lung cancer (NSCLC) cell lines. METHODS: Growth inhibitory effects of AG825 with various concentrations on three kinds of NSCLC cell lines, A549, H322 and H1299, were observed 24 and 96 hours after reaction respectively. Drug susceptibility test in vitro (MTT chromatometry) was used. RESULTS: Inhibition rate of AG825 on A549,H322,H1299 24 hours after administration was 24.03%,25.87%,17.35%, respectively; and 96 hours after administration (100 μm) was 78.31%,65.28%,63.98%, respectively.The half inhibitory concentration of AG825 to A549,H358,H1299 was 7.31,16.29,1.769 μm respectively. CONCLUSION: AG825 has growth inhibition effect on three kinds of NSCLC cell lines in a time and dosage dependent manner.